Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414815 | 1.00 | DGAT1 (0.46) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL26921601 | 0.85 | DGAT1 (0.39) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL25786431 | 0.85 | DGAT1 (0.42) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL2359261 | 0.84 | DGAT1 (0.39) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL23001552 | 0.84 | DGAT1 (0.41) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL2377204 | 0.83 | DGAT1 (0.38) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL908850 | 0.83 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL6521200 | 0.82 | DGAT1 (0.38) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL2318732 | 0.82 | DGAT1 (0.38) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL12904174 | 0.81 | DGAT1 (0.37) | DGAT1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ACLARIS THERAPEUTICS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4444721-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | BILLEDEAU ROLAND JOSEPH | 2011-01-27 | — | — | US | disclosed |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | BILLEDEAU ROLAND JOSEPH | 2011-01-27 | — | — | US | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063634-A1 | PYRROLOPYRAZINYL UREA KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | ROCHE PALO ALTO LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2009106443-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035373-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | JAK3, JAK1, JAK2 | DGAT1 4560/4885BRD4 690/4885CREBBP 3204/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | DGAT1 3958/4885BRD4 3826/4885CREBBP 437/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | DGAT1 4594/4885BRD4 630/4885CREBBP 672/4885 |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | DGAT1 2136/4885BRD4 2431/4885CREBBP 753/4885 |
| US-20090215788-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, JAK2 | DGAT1 4730/4885BRD4 697/4885CREBBP 2036/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | DGAT1 3942/4885BRD4 409/4885CREBBP 1056/4885 |
| US-12297203-B2 | Pyrrolopyrimidine ITK inhibitors | ITK, PDXK, DMPK | DGAT1 4090/4885BRD4 1658/4885CREBBP 2180/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | DGAT1 3592/4885BRD4 3756/4885CREBBP 273/4885 |
| US-20100144745-A1 | Pyrrolopyrazinyl Urea Kinase Inhibitors | JAK1, JAK3, ULK3 | DGAT1 4356/4885BRD4 407/4885CREBBP 1339/4885 |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | JAK3, JAK1, JAK2 | DGAT1 3958/4885BRD4 391/4885CREBBP 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.